Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29316635 | 0.82 | SMN1; SMN2 (0.55) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL29316633 | 0.79 | TSHR (0.47) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL5266072 | 0.75 | TSHR (0.50) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL14214398 | 0.74 | TSHR (0.65) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL21516451 | 0.74 | SMN1; SMN2 (0.49) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL36499 | 0.73 | TSHR (0.67) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL29316664 | 0.73 | TSHR (0.69) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL29316605 | 0.73 | TSHR (0.44) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL1402269 | 0.72 | TSHR (0.47) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL800995 | 0.72 | TSHR (0.60) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240244954-A1 | QUANTUM DOT LIGAND, QUANTUM DOT-LIGAND SYSTEM AND QUANTUM DOT MATERIAL | Beijing Boe Technology Development Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240244954-A1 | QUANTUM DOT LIGAND, QUANTUM DOT-LIGAND SYSTEM AND QUANTUM DOT MATERIAL | CDYL, CD2, CDYL2 | TSHR 1287/4885MAPK1 4240/4885SMN1; SMN2 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.